Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.05 | $0 | $0 |
| 2025 Q3 | -0.02 | $0 | $0 |
| 2025 Q2 | -0.02 | $0 | — |
| 2024 Q4 | -0.01 | $0 | -$426 |
| 2024 Q3 | -0.01 | $0 | -$426 |
| 2024 Q2 | -0.01 | $0 | -$1,387 |
| 2024 Q1 |
| -0.01 |
| $0 |
| -$1,387 |
| 2023 Q4 | -0.02 | $0 | -$655 |